Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8937323 | 1.00 | PDPK1 (0.47) | PDPK1ALDH1A1TSHRS1PR3PGR | |
| SCHEMBL8937317 | 1.00 | PDPK1 (0.47) | PDPK1ALDH1A1TSHRS1PR3PGR | |
| SCHEMBL8937228 | 0.84 | GAA (0.54) | PDPK1ALDH1A1S1PR3GAAMAPT | |
| SCHEMBL8937226 | 0.84 | GAA (0.54) | PDPK1ALDH1A1S1PR3GAAMAPT | |
| SCHEMBL8937230 | 0.84 | GAA (0.54) | PDPK1ALDH1A1S1PR3GAAMAPT | |
| SCHEMBL8937429 | 0.83 | S1PR3 (0.47) | PDPK1ALDH1A1S1PR3GAAMAPT | |
| SCHEMBL8937426 | 0.83 | S1PR3 (0.47) | PDPK1ALDH1A1S1PR3GAAMAPT | |
| SCHEMBL8937432 | 0.83 | S1PR3 (0.47) | PDPK1ALDH1A1S1PR3GAAMAPT | |
| SCHEMBL17802357 | 0.83 | TSHR (0.53) | PDPK1TSHRKMO | |
| SCHEMBL17802354 | 0.83 | TSHR (0.53) | PDPK1TSHRKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5559109-A | Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist | SANKKO COMPANY, LIMITED (JP) | 1996-09-24 | — | — | US | disclosed |
| US-5556852-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0395446-B1 | N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists | SANKYO CO (JP) | 1995-03-01 | — | — | EP | disclosed |
| US-5369106-A | N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists | SANKYO COMPANY, LIMITED (JP) | 1994-11-29 | — | — | US | disclosed |
| US-5192766-A | Platelet activating factor antagonist | SANKYO COMPANY, LIMITED (JP) | 1993-03-09 | — | — | US | disclosed |
| EP-0395446-A2 | N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists | Sankyo Company Limited (JP) | 1990-10-31 | — | — | EP | disclosed |